Welcome to our dedicated page for CEREW news (Ticker: CEREW), a resource for investors and traders seeking the latest updates and insights on CEREW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CEREW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CEREW's position in the market.
Cerevel Therapeutics, listed on Nasdaq under the ticker CERE, announced that its chairperson and CEO, Tony Coles, M.D., will speak at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am ET. The event will feature a live webcast available on the company's investor relations page, with a replay accessible after the event.
The company, focused on neuroscience diseases, has a pipeline of five clinical-stage therapies targeting conditions such as Parkinson's and schizophrenia. For more details, visit www.cerevel.com.
Cerevel Therapeutics (CERE) reported a strong cash position of $550.9 million as of March 31, 2022, bolstered by a $37.5 million risk-sharing arrangement in April 2022. The company is on track to initiate two Phase 2 trials for emraclidine in schizophrenia by mid-2022, with results expected in the first half of 2024. Positive results from the darigabat Phase 1 trial were announced, and data from its Phase 2 epilepsy trial is now anticipated in mid-2023. R&D expenses rose to $55.0 million in Q1 2022, reflecting ongoing clinical advancements.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its first quarter 2022 financial results on May 10, 2022, before U.S. markets open. Management will host a conference call at 8:00 a.m. ET to discuss these results and recent business updates. The call can be accessed domestically at (833)-665-0655 or internationally at (702)-495-1044, using conference ID 4497847. A live webcast will be available on the investors section of Cerevel’s website.
Cerevel Therapeutics (Nasdaq: CERE) announced key presentations at the American Academy of Neurology (AAN) Annual Meeting from April 2-7, 2022. Highlights include an oral presentation showcasing preclinical data on darigabat, demonstrating significant antiepileptic effects in drug-resistant focal seizures, comparable to diazepam. The company also revealed findings on tavapadon, a treatment for Parkinson’s disease, emphasizing its consistent pharmacokinetic profile across Phase 1 trials. Cerevel is focused on advancing its neuroscience drug pipeline to address unmet medical needs.
Cerevel Therapeutics (Nasdaq: CERE) announced that its CEO, Tony Coles, M.D., will participate in a fireside chat at the Stifel 4th Annual CNS Day on March 29, 2022, at 9:00 a.m. EDT. The event will highlight the company's commitment to addressing neuroscience diseases through its diversified pipeline, which includes six clinical-stage investigational therapies targeting conditions like schizophrenia and Parkinson’s disease. A live webcast will be available on Cerevel's investor relations website, along with a replay.
Cerevel Therapeutics announced positive results from a Phase 1 trial of darigabat for acute anxiety and is on track to initiate two Phase 2 trials of emraclidine for schizophrenia by mid-2022. The trials will involve 372 patients each, with results expected in the first half of 2024. Cerevel reported a cash position of $618 million as of December 31, 2021, a significant increase from $383.6 million in 2020. R&D expenses rose to $161.9 million, while G&A expenses grew to $58.2 million, reflecting ongoing investments in clinical programs and operations.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter 2021 financial results on March 1, 2022, before U.S. markets open. The company will host a conference call at 8:00 a.m. ET the same day to discuss the results and recent business updates. Interested parties can access the call by dialing designated numbers or via a live webcast on the company's investor website. Cerevel focuses on neuroscience diseases and has a diversified pipeline of investigational therapies.
Cerevel Therapeutics announced positive results from a Phase 1 trial of darigabat, a novel GABAA receptor PAM, showing significant anxiolytic effects in healthy volunteers. Both the 7.5 mg and 25 mg doses demonstrated a statistically significant improvement in Panic Symptoms List scores after eight days compared to placebo. The trial was well-tolerated with no serious adverse events reported. Cerevel plans to advance darigabat for anxiety-related disorders and is also conducting a Phase 2 trial for focal epilepsy. These developments position darigabat as a potential treatment innovation in anxiety management.
Cerevel Therapeutics announces emraclidine as the international nonproprietary name for CVL-231, an M4-selective positive allosteric modulator for schizophrenia. The company plans to initiate a Phase 2 program by mid-2022, with expected data in the first half of 2024. The Phase 1 trial for darigabat in acute anxiety has been completed, with data anticipated shortly. Additionally, the Phase 2a data for CVL-871 in dementia-related apathy is now expected in 1H 2023, delayed from 2H 2022 due to COVID-19. Cerevel's cash is projected to fund operations into 2024.
Cerevel Therapeutics (Nasdaq: CERE) announced that CEO Tony Coles will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET. Joining him will be CMO Raymond Sanchez and CSO John Renger for the Q&A session. Investors can access the live webcast on the company's investor relations website, with a replay available afterward. Cerevel focuses on treating neuroscience diseases, possessing a pipeline of six clinical-stage therapies aimed at conditions like Parkinson's, epilepsy, and schizophrenia.
